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BACKGROUND: Tamoxifen has been associated with an increased risk of stroke. There is, however, little information on the effect in the
post-treatment period. Using data from the Swedish Breast Cancer Group adjuvant trial of 5 vs 2 years of tamoxifen treatment, we
now report both short-term and long-term effects on morbidity as well as mortality because of cerebrovascular disease.
METHODS: Data from the Swedish National Hospital Discharge Registry combined with information from the Swedish Cause of Death
Registry was used to define events of disease. Hazard ratios (HRs) were estimated using Cox regression.
RESULTS: Comparing patients randomised to 5 years of tamoxifen with patients randomised to 2 years of tamoxifen, the incidence of
cerebrovascular diseases was increased (HR 1.70, 95% CI 1.05–2.75) during the active treatment phase and reduced after the active
treatment period (HR 0.78, 95% CI 0.63–0.96), and the difference in HR between the two time-periods was significant (P¼0.0033).
The mortality from cerebrovascular diseases was increased during the treatment period (HR 3.18, 95% CI 1.03–9.87) and decreased
during the post-treatment period (HR 0.60, 95% CI 0.40–0.90) with a significant difference in HR between the two periods of
follow-up (P¼0.0066). Similar results were seen for subgroups of cerebrovascular diseases, such as stroke and ischaemic stroke.
CONCLUSION: In an adjuvant setting, tamoxifen was associated with an increased risk of cerebrovascular disease during treatment, but a
decreased risk in the post-treatment period.
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In 1996 and 2005, we reported from a randomised tamoxifen trial
in postmenopausal women with early-stage breast cancer younger
than 75 years of age at surgery (Swedish Breast Cancer Cooperative
Group, 1996; Nordenskjo ¨ld et al, 2005). The all-cause mortality,
breast cancer-specific mortality and coronary heart disease
mortality were significantly reduced in the 5-year group, compared
with the 2-year group. We also saw a tendency to a decreased
mortality rate from cerebrovascular diseases in the 5-year group
compared with the 2-year group (hazard ratio (HR) 0.81, 95%
CI 0.53–1.23). The most recent EBCTG overview of randomised
trials shows a non-significant excess of mortality from stroke in
the group receiving about 5 years of adjuvant tamoxifen vs control
(Early Breast Cancer Trialists’ Collaborative Group, 2005). Several
meta-analyses of breast cancer risk reduction and treatment trials
showed that tamoxifen is associated with an increased risk of
stroke (Braithwaite et al, 2003; Bushnell and Goldstein, 2004;
Nelson et al, 2009). Many of the studies contributing to these meta-
analyses, however, have a limited follow-up time and there is little
information on the period after the termination of tamoxifen
treatment. With longer follow-up and with added data on
hospitalisations, we now report both short-term and long-term
effects on the incidence of cerebrovascular disease as well as
mortality from cerebrovascular diseases in the Swedish Hospital
Discharge Registry (HDR) and in the Swedish Cause of Death
Registry.
MATERIALS AND METHODS
The design and performance of the trial were described in detail in
the first report (Swedish Breast Cancer Cooperative Group, 1996).
The study included data from five of the six Swedish health care
regions; two of which used 20-mg daily doses of tamoxifen and
three of which used 40-mg. From 1983 to 1992, a total of 4610
patients were entered in the trial; of whom 4150 remained alive and
recurrence free at 2 years, and could thus contribute meaningful
information to the comparison of outcomes associated with
prolonged tamoxifen treatment. Of these 4150 patients, 32% were
o60 years of age at surgery, 12% older than 70 years, and 53%
were lymph-node positive. In total, 40% of the patients received
20-mg daily doses of tamoxifen and 60% were given 40-mg daily
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sdoses of tamoxifen. Among the patients who have breast cancer as
an underlying cause of death and no distant recurrence, we have
updated with new data on distant recurrences and used the date of
main diagnosis of breast cancer in HDR to substitute missing data
of distant recurrences. These additional data resulted in a
reduction of the number of patients from 4175 in our previous
report (Nordenskjo ¨ld et al, 2005) to 4150 patients.
In the analysis, the start date was 2 years after date of surgery
and patients were censored at date of death. Furthermore,
to avoid possible confounding effects of recurrence of breast
cancer and consequent treatment, each patient was considered to
be at risk for the analysed events up to, but not beyond, that of any
recurrence or contralateral breast cancer. Cox proportional
hazards modelling stratified by trial centre was used to estimate
hazard ratios and confidence intervals. Cumulative incidence of
cerebrovascular diseases was estimated by use of life-table
methods. To test for differences in HR between the follow-up
periods, an interaction term between treatment group and time
period was added to the Cox model. The effect of doses of
tamoxifen (20 vs 40mg) on cerebrovascular disease, during and
after active treatment, respectively, were checked, and no
significant difference in HR between the doses were detected. Also
the interaction effect of treatment and age at surgery (dichot-
omised at the median age; 63 years) on cerebrovascular disease
was checked, during and after active treatment, and none of the
interactions was significant.
RESULTS
An intention-to-treat analysis revealed that 5 years of tamoxifen
treatment compared with 2 years of tamoxifen treatment was
associated with an increased risk of cerebrovascular diseases (HR
1.70, 95% CI 1.05–2.75) during the active treatment phase and a
reduced risk after the active treatment period (HR 0.78, 95% CI
0.63–0.96) (Table 1 and Figure 1). The difference in HR associated
with cerebrovascular diseases between the two periods was
statistically significant (P¼0.0033). We also saw significant
differences in HR between the periods of follow-up for stroke
(P¼0.0056) and ischaemic stroke (P¼0.014), and similar
tendencies for haemorrhagic stroke, other and unspecified
cerebrovascular diseases and for TIA (Table 1). The mortality
from cerebrovascular diseases was increased during the treatment
period (HR 3.18, 95% CI 1.03–9.87) and decreased during the
post-treatment period (HR 0.60, 95% CI 0.40–0.90), with a
significant difference in HR between the periods of follow-up
(P¼0.0066). Similar significant differences in HR were obtained
when the data were not censored for contralateral breast cancer or
any recurrence (data not shown).
DISCUSSION
In the analysis, the date of main diagnosis from HDR or date of
death was used. We have not reviewed the diagnoses in this study,
but an earlier validation study showed a good precision of main
diagnosis in HDR for cerebrovascular diseases with sensitivity
95.7% and specificity 99.5% (Nilsson et al, 1994). After a median
follow-up after surgery of 12.1 years (range: 2.0–23.9 years), we
found a time-dependent effect of tamoxifen on the incidence of
cerebrovascular diseases. Our data confirm previous findings of
increased risk of cerebrovascular diseases in patients receiving
postoperative tamoxifen therapy (Braithwaite et al, 2003). There
are very few studies about the effect of tamoxifen on the incidence
of cerebrovascular diseases after the active treatment period.
Two studies have not been able to show that there is a decreased
risk of cerebrovascular disease during the post-treatment period
(McDonald et al, 1995; Cuzick et al, 2007). However, the women
Table 1 Morbidity and mortality from cerebrovascular disease according to randomised treatment (5 vs 2 years of tamoxifen) for the entire follow-up
(42 years after start of treatment), during treatment (2–5 years) and after treatment (45 years)
Number of events
Years since start
of treatment
2-year group
(n¼2114)
5-year group
(n¼2036)
Hazard ratio
(5 vs 2 years) (95% CI) P-value
a P diff.
Morbidity
Cerebrovascular diseases (430–8)
b 42 213 198 0.89 (0.73–1.08) 0.23
2–5 27 44 1.70 (1.05–2.75) 0.030
45 186 154 0.78 (0.63–0.96) 0.020 0.0033
Stroke (431, 433, 434, 436)
b 42 167 148 0.84 (0.67–1.05) 0.13
2–5 20 33 1.72 (0.99–3.00) 0.056
45 147 115 0.73 (0.57–0.93) 0.011 0.0056
Ischaemic stroke (433, 434)
b 42 115 119 0.98 (0.76–1.27) 0.89
2–5 13 26 2.10 (1.08–4.09) 0.029
45 102 93 0.85 (0.64–1.12) 0.25 0.014
Haemorrhagic stroke (431)
b 42 27 22 0.76 (0.43–1.33) 0.34
2–5 5 6 1.22 (0.37–3.99) 0.75
45 22 16 0.66 (0.35–1.26) 0.21 0.37
Other and unspecified cerebrovascular 42 76 79 0.99 (0.72–1.36) 0.97
diseases (430, 432, 435, 437, 438)
b 2–5 9 16 1.85 (0.82–4.19) 0.14
45 67 63 0.88 (0.63–1.25) 0.48 0.10
TIA (435)
b 42 14 17 1.22 (0.60–2.47) 0.59
2–5 4 8 2.07 (0.62–6.86) 0.24
45 10 9 0.88 (0.36–2.18) 0.79 0.27
Mortality
Cerebrovascular diseases (430–8)
b 42 62 50 0.75 (0.52–1.10) 0.14
2–5 4 12 3.18 (1.03–9.87) 0.045
45 58 38 0.60 (0.40–0.90) 0.014 0.0066
Abbreviations: CI¼confidence interval; P diff.¼P-value for difference in HR between the time-periods during and after treatment.
aTwo-sided Wald test.
bNinth International
Classification of Diseases code numbers.
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swere both pre- and postmenopausal and the number of events was
quite small in the treatment arms after tamoxifen was stopped.
Interestingly, the ATAC trial finds an excess risk of cerebrovas-
cular accidents during treatment in the tamoxifen arm compared
with the anastrozole arm (34 vs 20 events), but no difference off
treatment (20 vs 22 events) (ATAC Trialists’ Group, 2008).
Tamoxifen is associated with several of positive effects, for
example, lipid-lowering properties by decreasing total and low-
density lipoprotein cholesterol, and decreasing the levels of
C-reactive protein (CRP), which are known risk factors for
cardiovascular diseases, especially among postmenopausal women
(Cushman et al, 2001). Tamoxifen increases the risk of venous
thromboembolism in women with breast cancer, but its relation-
ship to stroke is uncertain. As a result of the pro-thrombotic
properties, tamoxifen may be associated with cerebral venous
thrombosis (Bushnell and Goldstein, 2004). Tamoxifen exerts
oestrogenic effects in several human tissues. As compared with the
data from randomised trials with oestrogen therapy (Magliano
et al, 2006), our data with tamoxifen show similar effects on
cerebrovascular disease during the active treatment phase.
However, cerebrovascular mortality and morbidity in the oestro-
gen trials were not analysed for the long-term effects, which we
have described in this report. The time-dependent effects of
tamoxifen on cerebrovascular disease in the present study thus
might be the result of a combination of positive and negative
effects of the treatment. However, as the biological mechanisms are
poorly understood, the long-terms effects of tamoxifen should be
interpreted with caution.
In summary, this trial showed a time-dependent effect of
postoperative tamoxifen treatment, with a significantly increased
risk of morbidity and mortality from cerebrovascular diseases
during the active treatment phase and significantly decreased risks
after the active treatment period. The difference in HR between the
two follow-up periods was statistically significant for cerebrovas-
cular diseases, as well as for mortality from cerebrovascular
diseases. Also, for stroke and ischaemic stroke there was a
statistically significant difference. These results stress the im-
portance of obtaining long-term follow-up data from adjuvant
trials also comparing tamoxifen with aromatase inhibitor, as well
as from prevention trials comparing tamoxifen with other
chemopreventive agents (Visvanathan et al, 2009). Our finding
of a benefit of tamoxifen on cerebrovascular risk in the post-
treatment phase is new and needs to be confirmed by more data
from other studies.
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morbidity
Tamoxifen 2 years, 
mortality
Tamoxifen 5 years, 
mortality
Patients at risk, morbidity: 
2 years:                                      1718                                    1272                                     492                                     70 
5 years:                                      1686                                    1360                                     543                                     74
Patients at risk, mortality:  
2 years:                                       1739                                    1322                                     531                                     81 
5 years:                                       1714                                    1424                                     598                                     83
Cumulative morbidity (%), 95%  CI:
2 years:                                       1.4, 0.9–2.0                           6.7, 5.5–8.0                          14.9, 12.8–17.0                  22.4, 18.3–26.6
5 years:                                       2.3, 1.7–3.0                         6.6, 5.4–7.8                          13.3, 11.4–15.2                  18.0, 14.7–21.4   
Cumulative mortality (%), 95%    CI:
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5 years:                                       0.7, 0.3–1.0                         1.5, 0.9–2.1                           3.0, 2.1–4.0                        5.3, 3.0–7.6
Figure 1 Cumulative morbidity and mortality from cerebrovascular diseases among patients randomly assigned to 2 years (n¼2114) or 5 years
(n¼2036) of adjuvant tamoxifen therapy. Patients at risk and cumulative risk estimates with 95% confidence intervals (CI) are given at 5, 10, 15 and 20 years
after start of treatment.
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